Senhwa Biosciences, Inc.
6 clinical trials · Sponsor
◉ Watch Senhwa Biosciences, Inc.
| Record | Firm | Date |
|---|---|---|
| CX-4945 in Viral Community Acquired Pneumonia (NCT06202521) | Senhwa Biosciences, Inc. | 2024-03-20 |
| A Study of Silmitasertib (CX-4945) in Healthy Subject (NCT05817708) | Senhwa Biosciences, Inc. | 2022-11-28 |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation (NCT04890613) | Senhwa Biosciences, Inc. | 2021-09-08 |
| Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 (NCT04663737) | Senhwa Biosciences, Inc. | 2020-11-30 |
| Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) (NCT03897036) | Senhwa Biosciences, Inc. | 2019-04-16 |
Track Senhwa Biosciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.